FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

| OMB Number: | 3235-0287 |
|--------------------------|-----------|
| Estimated average burder | n |
| hours per response. | 0.5 |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| affirmative defense 10b5-1(c). See Insti | | | | |
|---|---|---------|---|--|
| 1. Name and Address BUCHI J KEV | of Reporting Person* | | 2. Issuer Name and Ticker or Trading Symbol Benitec Biopharma Inc. [BNTC] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) |
| (Last) | Last) (First) (Middle) C/O BENITEC BIOPHARMA INC. | | 3. Date of Earliest Transaction (Month/Day/Year) 08/11/2023 | X Director 10% Owner Officer (give title Other (specify below) below) |
| 3940 TRUST WA | | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person |
| (Street) | | 0.4.4.5 | | Tom med by word than one reporting relicon |
| HAYWARD | CA | 94545 | | |
| (City) | (State) | (Zip) | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | Transaction Code (Instr. | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported | Form: Direct (D) | Beneficial Ownership |
|---------------------------------|--|---|--------------------------|---|--|---|------------------------------------|--|------------------|-------------------------|
| | | | Code | v | Amount (A) or (D) Price | | Transaction(s) (Instr. 3 and 4) | | (Instr. 4) | |
| Common Stock | 08/11/2023 | | P | | 51,813(1) | A | (1) | 52,097(2) | D | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transac Code (In 8) | | Disposed | ivative Expiration Date | | d 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | |
|---|---|--|---|---------------------------------|---|-----------------------|-------------------------|---------------------|--|-----------------|--------------------------------------|--|--|--|--|
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | Transaction(s) (Instr. 4) | | |
| Common Warrants (right to buy) | \$3.86 | 08/11/2023 | | P | | 51,813 ⁽¹⁾ | | 08/11/2023 | 08/11/2028 | Common Stock | 51,813 | (1) | 51,813 | D | |

Explanation of Responses:

1. Represents shares of common stock, par value \$0.0001 per share (the "Common Stock") purchased together with common warrants to purchase shares of Common Stock in the Issuer's registered underwritten offering on August 11, 2023 for a purchase price of \$1.93.

2. The reported number of shares has been adjusted to reflect the impact of the Issuer's 17-for-1 reverse stock split completed on July 26, 2023.

<u>/s/ J. Kevin Buchi</u> <u>08/14/2023</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.